Broad-Spectrum Anti-Microbial Vaccine Candidate Collaboration Established

Alopexx, Inc. today announced a collaboration with India-based Bharat Biotech for the co-development and commercialization of the broad-spectrum antimicrobial vaccine, AV0328.

AV0328 is a synthetic vaccine designed to target poly N-acetyl glucosamine (PNAG), a substance found on the surface of a wide range of bacterial, fungal, and parasitic pathogens.

In preclinical studies, targeting PNAG has shown effectiveness in preventing and treating infections caused by over 15 different pathogens.

A phase I, first-in-human clinical trial, has been completed, demonstrating that AV0328 is well-tolerated with no serious adverse events observed. The vaccine-induced antibodies are capable of killing a wide range of PNAG-expressing pathogens, reaffirming their potential as a broad-spectrum antimicrobial solution.

Dr. Krishna Ella, Executive Chairman of Bharat Biotech, commented in a press release on September 11, "024: We are proud to collaborate with Alopexx to bring AV0328 to the regions (India) where it is most needed."

"Our goal is to develop solutions to reduce antimicrobial resistance through vaccination. This collaboration aligns with our mission to provide safe, affordable, and high-quality vaccines to combat infectious diseases globally."

The companies will co-develop and commercialize AV0328 in India and other licensed territories as part of the collaboration.

This Review discusses evidence that vaccines can play a major role in fighting antimicrobial resistance (AMR).

Different health organizations have highlighted the emergence and spread of AMR as a global threat. Pathogens resistant to AMR cause substantial morbidity and death. As resistance to multiple drugs increases, novel and effective therapies and prevention strategies are needed, wrote researchers in 2022.